Hinova Pharmaceuticals Inc. announced that it has received $147,300,000 in a round of funding on October 2, 2020. The transaction included participation from CCB International Asset Management Ltd., Shenzhen Investment Holding Capital Co., Ltd., Hangzhou Tigermed Consulting Co.,Ltd (SZSE:300347), Huarong Rongde Asset Management Co., Ltd., Hongtai Capital Holdings, Infinity Ventures, Founder H Fund Co., Ltd., Sealand Innovation Capital Investment Management Co., Ltd. and DiNovA Venture Capital.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.32 CNY | -1.12% |
|
+6.87% | -45.61% |
Apr. 26 | Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 08 | China Stocks Fall Ahead of March Economic Data Release | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-45.61% | 386M | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- 688302 Stock
- News Hinova Pharmaceuticals Inc.
- Hinova Pharmaceuticals Inc. announced that it has received $147.3 million in funding from a group of investors